AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines

J Am Acad Child Adolesc Psychiatry. 2024 Jul;63(7):663-665. doi: 10.1016/j.jaac.2024.02.008. Epub 2024 Feb 28.

Abstract

Despite decades of clinical use and a large body of evidence, the WHO continues to exclude methylphenidate for attention-deficit/hyperactivity disorder (ADHD) from its EML.1 The exclusion of methylphenidate has dire implications for millions of individuals with ADHD worldwide, especially those living in low and low-middle income countries (LMIC), where governmental decisions to make medicines available are contingent on EML listing.

Publication types

  • Letter

MeSH terms

  • Attention Deficit Disorder with Hyperactivity* / drug therapy
  • Central Nervous System Stimulants* / pharmacology
  • Central Nervous System Stimulants* / therapeutic use
  • Child
  • Drugs, Essential
  • Humans
  • Methylphenidate* / pharmacology
  • Methylphenidate* / therapeutic use
  • World Health Organization*

Substances

  • Methylphenidate
  • Central Nervous System Stimulants
  • Drugs, Essential